Enzymes are leading targets for the design and development of therapeutic small molecules and numerous LSD1 inhibitors have, already, been described in the literature [63] with some of them undergoing clinical trials for different types of leukemia and solid tumors (not including breast cancer). Here, KDM1A is linked to breast cancer.